Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Completion of 30-day review for clinical trial notification for Phase I/II study of HS-005 (catheter administration)
Supplemental comments regarding termination of partnership with Novo Nordisk AS (#3)
Notice of submission of clinical trial notification for Phase I/II study of HS-005 targeting severe HF due to IHD and DCM
Supplemental comments regarding termination of partnership with Novo Nordisk AS (#2)
Supplemental comments regarding termination of partnership with Novo Nordisk AS
Notice regarding termination of partnership with Novo Nordisk AS
Notice regarding the new partner for delivery catheter system for allogeneic iPS cell-derived cardiomyocyte spheroids
Non-consolidated Financial Results for the Nine Months Ended July 31, 2025 (Under Japanese GAAP)
Notice Regarding the Revisions of Full-Year Financial Results Forecast for the Fiscal Year Ending December 31, 2025
Notice Regarding Selection as Loan Margin Trading Isssue
Notice of Change in the Status of Major Shareholder
Notice of Non-operating Expenses (Foreign Exchange Losses)
Non-consolidated Financial Results for the Six Months Ended April 30, 2025 (Under Japanese GAAP)
Financial Results for the Three Months Ended January 31, 2025 (Under Japan GAAP)(Non-consolidated)
Notice Regarding the Launch of the Analyst Report Issued by Shared Research Inc.
Notice Regarding the Completion of the enrollment in Phase 1/2 Clinical Trial (LAPiS Study)
[Delayed]Financial Results for the Fiscal Year Ended October 31, 2024 (Under Japan GAAP)(Non-consolidated)
Notice Regarding the LAPiS Study Progress
Notice Regarding the Revisions of Full-Year Financial Results Forecast for the Fiscal Year Ending October 31, 2024
[Delayed] Financial Results for the Nine Months Ended July 31, 2024 (Under Japan GAAP)(Non-consolidated)